Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Chemotherapy Initiation and Ovarian Cancer Survival

Gynecol Oncol; ePub 2016 Oct 19; Chan, et al

Early initiation of chemotherapy was not associated with improved survival in patients with early-stage ovarian cancer, a recent study found. This analysis of NRG oncology/gynecologic oncology group trials included 497 stage I-III epithelial ovarian cancer patients and sought to determine the association between timing of adjuvant therapy initiation and survival. Researchers found:

  • Median time between surgery and initiation of adjuvant therapy was 23 days; time interval from surgery to initiation of adjuvant therapy was categorized into 3 groups: <2 weeks, 2 to 4 weeks, and >4 weeks.
  • Corresponding 5-year recurrence-free survival rates were 72.8%, 73.9%, and 79.5%, respectively.
  • 5-year overall survival rates were 79.4%, 81.9%, and 82.8%, respectively.
  • Hazard ratio for recurrence-free survival was 0.90 for 2 to 4 weeks and 0.72 for >4 weeks.

Citation:

Chan JK, Java JJ, Fuh K, et al. The association between timing of initiation of adjuvant therapy and the survival of early state ovarian cancer patients – An analysis of NRG oncology/gynecologic oncology group trials. [Published online ahead of print October 19, 2016]. Gynecol Oncol. doi:10.1016/j.ygyno.2016.09.015.